Selective COX-2 inhibitors: Are they safe for the stomach?

Gastroenterology

Volumn 115, Issue 1, 1998, Pages 227-229

  Yeomans, N D ^a   Cook, G A ^a   Giraud, A S ^a  

^a WESTERN HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

6 (2,4 DIFLUOROPHENYLTHIO) 5 METHANESULFONAMIDO 1 INDANONE; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; ETODOLAC; FLOSULIDE; INDOMETACIN; ISOENZYME; MELOXICAM; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM;

ANIMAL MODEL; DRUG ACTIVITY; DRUG SAFETY; DRUG SCREENING; EDITORIAL; EXPERIMENTAL MODEL; HUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; STOMACH EROSION; STOMACH MUCOSA;

EID: 0031747076     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0016-5085(98)70388-9     Document Type: Editorial

References (29)

1. JR Vane Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs Nature 231 1971 232 234
2. EA Meade WL Smith DL DeWitt Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs J Biol Chem 268 1993 6610 6614
3. DL DeWitt EA Meade WL Smith PGH synthase isoenzyme selectivity: the potential for safer nonsteroidal antiinflammatory drugs Am J Med 95 suppl 2A 1993 40S 44S
4. JR Vane RM Botting Mechanism of action of nonsteroidal anti-inflammatory drugs Am J Med 104 1998 2S 8S
5. JL Wallace A Bak W McKnight S Asfaha KA Sharkey WK MacNaughton Cyclooxygenase 1 contributes to inflammatory responses in rats and mice: implications for gastrointestinal toxicity Gastroenterology 115 1998 101 109
6. K Seibert Y Zhang K Leahy S Hauser J Masferrer W Perkins L Lee P. Isakson Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain Proc Natl Acad Sci USA 91 1994 12013 12017
7. JL Masferrer BS Zweifel PT Manning SD Hauser KM Leahy WG Smith PC Isakson K. Seibert Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic Proc Natl Acad Sci USA 91 1994 3228 3232
8. CC Chan S Boyce C Brideau AW Ford-Hutchinson R Gordon D Guay RG Hill CS Li J Mancini M Penneton Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745,337: a novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach J Pharmacol Exp Ther 274 1995 1531 1537
9. T Hirata H Ukawa H Yamakuni S Kato K. Takeuchi Cyclooxygenase isozymes in mucosal ulcerogenic and functional responses following barrier disruption in rat stomachs Br J Pharmacol 122 1997 447 454
10. AA Shah FE Murray B Thjodleifsson E Oddsson H Gudjonsson DJ Fitzgerald I. Bjarnason Nimesulide, a selective COX-2 inhibitor, causes less gastrointestinal damage compared with naproxen: a prospective study in human volunteers (abstr) Gastroenterology 114 1998 A283
11. 2 formation in tissue form human colonic mucosa and chronic bursitis (abstr) Gastroenterology 114 1998 A139
12. N Maricic K Ehrlich R Schuligoi M Respondek BM Peskar Cyclooxygenase-2-derived prostaglandins contribute to mucosal resistance to ischaemia/reperfusion injury in the rat stomach (abstr) Gastroenterology 114 1998 A215
13. H Mizuno C Sakamoto K Matsuda K Wada T Uchida H Noguchi T Akamatsu M. Kasuga Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice Gastroenterology 112 1997 387 397
14. S Takahashi J Shigeta N Kobayashi S. Okabe Localization of cyclooxygenase-2 and regulation of its expression in gastric ulcers in rats (abstr) Gastroenterology 114 1998 A303
15. B Gretzer K Ehrlich N Maricic N Lambrecht M Respondek BM Peskar Selective cyclo-oxygenase-2 inhibitors and their influence on the protective effect of a mild irritant in the rat stomach Br J Pharmacol 123 1998 927 935
16. J Shigeta S Takahashi M Ishikawa S. Okabe Role of cyclooxygenase-2 (COX-2) in the healing of gastric ulcers in rats (abstr) Gastroenterology 114 1998 A285
17. BK Reuter S Asfaha A Buret KA Sharkey JL Wallace Exacerbation of inflammation-associated colonic injury in rat through inhibition of cyclooxygenase-2 J Clin Invest 98 1996 2076 2085
18. S Nakatsugi N Terada T Yoshimura Y Horie M. Furukawa Effects of nimesulide, a preferential cyclooxygenase-2 inhibitor, on carrageenan-induced pleurisy and stress-induced gastric lesions in rats Prostaglandins Leukot Essent Fatty Acids 55 1996 395 402
19. A Schmassmann BM Peskar C Stettler P Netzer T Stroff B Flogerzi F. Halter Effects of inhibition of prostaglandin endoperoxide synthase-2 in chronic gastro-intestinal ulcer models in rats Br J Pharmacol 123 1998 795 804
20. PE Lipsky PC Isakson Outcome of specific COX-2 inhibition in rheumatoid arthritis J Rheumatol 24 suppl 49 1997 9 14
21. A. Barner Review of clinical trials and benefit/risk ratio of meloxicam Scand J Rheumatol 102 Suppl 1996 29 37
22. J Hayllar I. Bjarnason Gastroduodenal tolerability of highly specific cyclo-oxygenase-2 inhibitor Ital J Gastroenterol 28 suppl 4 1996 30 32
23. S Noble JA Balfour Meloxicam Drugs 51 1996 424 430
24. L Patoia L Santucci P Furno MS Dionisi S Dell'Orso M Romagnoli A Sattarinia MG Marini A 4-week, double-blind, parallel-group study to compare the gastrointestinal effects of meloxicam 7.5 mg, meloxicam 15 mg, piroxicam 20 mg and placebo by means of faecal blood loss, endoscopy and symptom evaluation in healthy volunteers Br J Rheumatol 35 suppl 1 1996 61 67
25. J Hosie M Distel E. Bluhmki Meloxicam in osteoarthritis: a 6-month, double-blind comparison with diclofenac sodium Br J Rheumatol 35 suppl 1 1996 39 43
26. EC Huskisson R Ghozlan R Kurthen FL Degner E. Bluhmki A long-term study to evaluate the safety and efficacy of meloxicam therapy in patients with rheumatoid arthritis Br J Rheumatol 35 suppl 1 1996 29 34
27. JY Reginster M Distel E. Bluhmki A double-blind, three-week study to compare the efficacy and safety of meloxicam 7.5 mg and meloxicam 15 mg in patients with rheumatoid arthritis Br J Rheumatol 35 suppl 1 1996 17 21
28. I Bjarnason A Macpherson H Rotman J Schupp J. Hayllar A randomized, double-blind, crossover comparative endoscopy study on the gastroduodenal tolerability of a highly specific cyclooxygenase-2 inhibitor, flosulide, and naproxen Scand J Gastroenterol 32 1997 126 130
29. D Henry LL Lim LA Garcia Rodriguez S Perez Gutthann JL Carson M Griffin R Savage R Logan Y Moride C Hawkey S Hill JT Fries Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis Br Med J 312 1996 1563 1566